European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents

Rhea-AI Summary

HeartSciences (Nasdaq: HSCS) received European Patent No. EP4252651 for ECG-based assessment of diastolic function, effective as a Unitary Patent from April 29, 2026.

The patent covers AI-driven machine-learning models using ECG and demographic data, extends protection to 19 European countries, and brings HeartSciences’ portfolio to more than 45 granted patents.

Positive

• European Patent EP4252651 granted for ECG-based diastolic function assessment
• Unitary Patent protection across 19 European countries from April 29, 2026
• Patent covers AI machine-learning models using ECG and demographic data
• Intellectual property portfolio expanded to more than 45 granted patents
• Company cites meaningful commercial advantage as AI-ECG field expands

Negative

• None.

Market Context

This announcement reinforces HeartSciences’ AI‑ECG strategy by adding a European Unitary Patent for ...

Analysis

This announcement reinforces HeartSciences’ AI‑ECG strategy by adding a European Unitary Patent for ECG‑based assessment of diastolic function, bringing its portfolio to more than 45 granted patents across 19 European countries. In the past months, the company has combined IP building with commercial steps such as Epic integration and initial SaaS agreements. Investors may watch for how this patent supports product adoption, reimbursement traction, and future commercial partnerships.

Key Figures

Patent number: EP4252651 European coverage: 19 countries Patent portfolio size: More than 45 granted patents

3 metrics

Patent number EP4252651 European Patent Office grant for ECG-based assessment of diastolic function

European coverage 19 countries Unitary Patent coverage across specified European countries

Patent portfolio size More than 45 granted patents HeartSciences’ global intellectual property portfolio after this grant

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	Product/AI launch	Positive	+2.0%	Launched MyoVista Insights 1.3 with AI-ECG marketplace and first FDA-cleared algorithm.
May 19	Commercial agreement	Positive	+1.1%	Signed commercial deployment agreement with North Shore Health within Cibolo Health network.
May 05	First SaaS revenues	Positive	-0.5%	Announced first mainstream SaaS revenue agreement for MyoVista Insights platform.
Apr 14	Governance/update	Neutral	+0.5%	Reminder for shareholders to vote ahead of the April 30 virtual annual meeting.
Mar 25	Integration milestone	Positive	+1.7%	MyoVista Insights received Epic Toolbox designation for ECG Management System integration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent commercial and product updates have usually seen modestly positive price reactions, with one notable divergence on a SaaS agreement.

Recent Company History

Over the last few months, HeartSciences has focused on commercializing its AI‑ECG platform and deepening integrations. On Mar 25, MyoVista Insights received Epic Toolbox designation, followed by its first SaaS revenue agreement on May 5. Subsequent deals with North Shore Health on May 19 and an AI‑ECG marketplace launch on Jun 2 generally produced small positive moves. Today’s European patent grant extends this trajectory of building the AI‑ECG ecosystem and IP base.

Key Terms

electrocardiography, electrocardiogram, diastolic function, echocardiogram, +3 more

7 terms

electrocardiography medical

"a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”)"

Electrocardiography is a medical test that records the heart’s electrical signals using sensors on the skin, producing a tracing that shows heart rhythm and timing. Investors should care because these readings are routinely used to assess the safety and effectiveness of drugs, medical devices, and treatments—like checking a building’s wiring for faults—so abnormal results can affect clinical trial outcomes, regulatory approval, and product marketability.

electrocardiogram medical

"titled “Electrocardiogram-Based Assessment of Diastolic Function.”"

An electrocardiogram (ECG or EKG) is a simple, noninvasive test that records the heart’s electrical signals through sensors on the skin and displays them as a waveform showing heart rate and rhythm. For investors, ECGs are important because they are a primary tool for diagnosing heart conditions, monitoring safety and effectiveness in clinical trials, and driving demand for medical devices and services—like a dashboard gauge revealing whether a car’s engine is healthy.

diastolic function medical

"Electrocardiogram-Based Assessment of Diastolic Function."

Diastolic function is the heart’s ability to relax and fill with blood between beats, like a balloon that must loosen to take in air before the next squeeze. It matters to investors because impaired filling can drive demand for drugs, devices, hospital care and long‑term treatment costs, influence regulatory reviews and trial outcomes, and affect productivity and insurance risk — all of which can change a company’s revenues and valuations.

echocardiogram medical

"estimate echocardiogram parameters indicative of diastolic function using ECG data"

An echocardiogram is a noninvasive ultrasound scan that creates a moving picture of the heart’s chambers, valves and blood flow—like a live camera or sonar for the heart. Investors track echocardiograms because results influence clinical diagnoses, drug and device trial outcomes, regulatory decisions and patient treatment plans, all of which can affect a healthcare company’s revenues, liability risk and market outlook.

machine learning technical

"The patented technology uses machine learning models, trained on ECG and echocardiography data"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

artificial intelligence technical

"through the integration of artificial intelligence (“AI”), today announced the grant"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

unitary patent regulatory

"The patent took effect as a Unitary Patent on April 29, 2026"

A unitary patent is a single patent right that provides uniform protection across multiple participating countries in a region, replacing the need to maintain separate national patents in each country. For investors, it matters because it can reduce the cost and complexity of protecting and enforcing key technologies across markets, affecting a company’s competitive moat, licensing revenue potential, and the scale and cost of patent litigation—similar to holding one passport instead of many.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function

Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced the grant by the European Patent Office (EPO) of European Patent No. EP4252651, titled “Electrocardiogram-Based Assessment of Diastolic Function.” The patent covers machine-learning models and methods for computing quantitative estimates of echocardiogram parameters indicative of diastolic function using ECG data and patient demographic parameters.

“Securing European patent protection for ECG-based assessment of diastolic function is an important expansion of our AI-ECG intellectual property portfolio,” said Andrew Simpson, CEO of HeartSciences. “Diastolic dysfunction is an important indicator of cardiac disease that has traditionally required imaging-based assessment. This grant further reinforces our strategy of transforming the ECG into a far more valuable front-line cardiac screening tool and underlines the considerable embedded IP value in HeartSciences. We believe the breadth of our patent portfolio provides a meaningful commercial advantage as the field of AI-ECG continues to expand.”

The patented technology uses machine learning models, trained on ECG and echocardiography data, to estimate echocardiogram parameters indicative of diastolic function directly from a patient’s ECG.

The patent took effect as a Unitary Patent on April 29, 2026, and provides coverage in 19 European countries: Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Sweden. With this grant, HeartSciences’ intellectual property portfolio now includes more than 45 granted patents.

For more information, please visit: https://www.heartsciences.com. X: @HeartSciences

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. All statements, other than statements of historical facts, included herein are “forward-looking statements” including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences’ other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations:

Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us

Media Contact:

HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com

FAQ

What European patent did HeartSciences (HSCS) receive on June 11, 2026?

HeartSciences received European Patent No. EP4252651 for ECG-based assessment of diastolic function. According to HeartSciences, the patent covers machine-learning models estimating echocardiogram parameters using ECG data and patient demographics, strengthening its AI-ECG intellectual property portfolio.

How does the new HSCS European patent use ECG data for diastolic function assessment?

The patent uses machine-learning models trained on ECG and echocardiography data to estimate echocardiogram parameters. According to HeartSciences, these models compute quantitative indicators of diastolic function directly from a patient’s ECG combined with demographic parameters, potentially enhancing front-line cardiac screening.

Which countries are covered by HeartSciences’ Unitary Patent EP4252651 for AI-ECG technology?

Unitary Patent EP4252651 provides coverage in 19 European countries. According to HeartSciences, these include Austria, Belgium, France, Germany, Italy, the Netherlands, Portugal, Sweden and others, expanding protection for its ECG-based diastolic function assessment technology across much of Europe.

What does the new European patent mean for HeartSciences’ (HSCS) intellectual property portfolio?

The grant increases HeartSciences’ portfolio to more than 45 granted patents. According to HeartSciences, securing European protection for ECG-based diastolic function assessment supports its strategy to transform ECG into a more valuable screening tool and may offer commercial advantages in AI-ECG.

When did HeartSciences’ European Patent EP4252651 for HSCS take effect as a Unitary Patent?

The European Patent EP4252651 took effect as a Unitary Patent on April 29, 2026. According to HeartSciences, this status provides uniform protection for its ECG-based diastolic function assessment technology across 19 participating European countries.